

Press Release

15 May 2025 17:20:00 CEST

2cureX AB (2CUREX) Launches “Operation Twin Code” with New Investors, Leadership Transition, and Global Roadmap

2cureX AB (Ticker: 2UREX), a leader in functional precision oncology, announces the initiation of an ambitious multi-phase commercial and clinical expansion strategy, codenamed Operation Twin Code, aimed at transforming patient outcomes and driving shareholder value.

As part of this next chapter, 2CUREX welcomes that our cornerstone investor provides a loan of 4,5 million SEK as part of an earlier commitment to provide 2-3 mEUR loan as working capital. Their investments significantly strengthen the company’s financial position and support the planned cash dividend distribution to shareholders.

In line with these developments, Dan Honeywell will step down as Chief Executive Officer and Board Member, effective 15. May 2025. Board member Nathaniel Hutley will assume the role of interim CEO while the Board conducts discussions with candidates possessing extensive oncology and commercial experience to lead 2CUREX into this new global growth phase.

Dan Honeywell commented:

“I’m proud of what we achieved in strengthening the company’s commercial footprint. With bold new plans underway and outstanding new investors, now is the right time for me to step back. I remain fully supportive of 2CUREX’s mission.”

2cureX is also pleased to announce that Prof. Dr. Jacob Scott, physician-scientist at the Cleveland Clinic and internationally respected leader in oncology innovation, will join the company’s newly formed Global Advisory Board. Prof. Dr. Scott joins as the company prepares to unveil new clinical partnerships

Prof. Dr. Jacob Scott said:

“2CUREX’s technology is uniquely positioned to advance personalised cancer treatment. Functional precision oncology is rapidly becoming central to achieving better patient outcomes, and these latest developments will help accelerate clinical adoption.”

Ole Thastrup, Chairman of the Board, added:

“Dan has been instrumental in positioning 2CUREX for this next step. Alongside powerful upcoming announcements and strategic roadmap, we are building the foundation for a company that will lead globally. Our gratitude goes to Dan and we wish him success in his future endeavours.”

This press release marks the first step of Operation Twin Code, which over the coming months will unveil further major news, including Direct to Patient commercialization, new partnerships, advisory board expansions, investor engagement programs, and what we believe will ultimately bring not only financial returns but also significant health benefits to patients and shareholders alike.

2CUREX remains fully committed to transforming functional precision oncology from a scientific frontier into a routine clinical standard.

For more information about 2cureX:

Ole Thastrup, Chairman of the Board

E-mail: ot@2curex.com

Telephone: +45 2211 5399

Kenneth Graabek Johansen, Chief Financial Officer

E-mail: kgj@2curex.com

Telephone: +45 23 49 02 27

About 2cureX

2cureX is a leader in cancer drug sensitivity testing and has developed the IndiTreat® (Individual Treatment) family of tests. Starting from a sample of the patient's tumor, IndiTreat® creates thousands of 3D replicas (tumoroids) and predicts the tumor response to the different available drugs, providing the physician with valuable information to make the treatment decisions.

The first three IndiTreat® tests are aimed at optimizing treatment decisions in patients with metastatic colorectal cancer (IndiTreat® Start for first line of therapy, IndiTreat® Extend and Explore for third line). Additional tests are under development to cover other stages of colorectal cancer as well as other gastrointestinal cancers.

According to several reports, the total yearly expenditure in cancer-related In Vitro Diagnostic (IVD) tests exceeds 17.5Bn USD worldwide, from which 2.5 Bn USD are tests directly related to therapy decision making, with a CAGR of 12.7%. Despite this, only one third of all cancer treatments are supported by one of these tests. IndiTreat® aims at filling this gap and making Precision Oncology available to all cancer patients.

The company is listed on Nasdaq First North Growth Market in Stockholm (symbol: "2CUREX"). For more information about 2cureX visit www.2cureX.se

Certified Adviser: Redeye AB

This information is information that 2cureX is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 2025-05-15 17:20 CEST.

Attachments

[2cureX AB \(2CUREX\) Launches “Operation Twin Code” with New Investors, Leadership Transition, and Global Roadmap](#)